Online Courses for Other HCP's

A complete listing of currently available online programs is provided below. To access course materials and claim credit you must be registered and logged-in. Courses of interest must be selected and added to your FCMCME.org user account. Once selected course material links will be provided from within your individual User Record section of this website.

Sort by: Title | Newest
Anticoagulation Reversal: Case 1 - Sensible Risk Stratification
Presented by: Peter J. Kudenchuk, MD
Effective Date: August 15, 2017
Expiration Date: August 14, 2019
Credits: .5
Format: Webinar
Fee: Free
16884

This interactive case study discussion will provide the knowledge and tools to enable the primary care provider to use scoring systems such as the CHADS-VASc,and HAS-BLED to stratify patients risk potential for bleeding due to anticoagulation therapy.

Case: A 40-year old male from the Xinjiang Province in China presents with ischemic stroke, category 4 on the LAMS (Los Angeles Motor Scale). He is a crewmember on a Chinese freighter offloading in a U. S. port city when he collapses and is rushed to a local hospital. The captain has no information on the crewmember’s medical history but notes that the patient is a heavy smoker and tends to binge drink when portside.

Outcome Objectives:

  • Utilize scoring systems (CHADS-VASc, HAS-BLED) to risk-stratify patients considered for anticoagulation therapies and mitigate their bleeding risk

Funded through an educational grant from Portola Pharmaceuticals Inc.

Selection Required to View & Claim Credit

Anticoagulation Reversal: Case 2 - Converting Between Anticoagulants
Presented by: Peter J. Kudenchuk, MD
Effective Date: August 15, 2017
Expiration Date: August 14, 2019
Credits: .5
Format: Webinar
Fee: Free
16885

This interactive case study discussion will provide the knowledge and tools to enable the primary care provider to explain the incidence and sources of bleeding related to the use of oral anticoagulants and its impact on health care; compare the difference in bleeding risk between oral vitamin K antagonists and direct oral anticoagulants (DOACs) and be able to convert from one anticoagulant to another.

Case: A 57-year old Alaska Native female has been taking Warfarin for several years for non-valvular AF and wishes to switch to one of the newer DOACs, which she hears are safer.

Outcome Objectives:

  • Explain the incidence and sources of bleeding related to the use of oral anticoagulants and its impact on health care.
  • Compare the difference in bleeding risk between oral vitamin K antagonists and direct oral anticoagulants (DOACs).
  • Describe a strategy for conversion from one anticoagulant to another

Funded through an educational grant from Portola Pharmaceuticals Inc.

Selection Required to View & Claim Credit

Anticoagulation Reversal: Case 3 - Reversing Anticoagulation
Presented by: Peter J. Kudenchuk, MD
Effective Date: August 15, 2017
Expiration Date: August 14, 2019
Credits: .5
Format: Webinar
Fee: Free
16886

This interactive case study discussion will provide the knowledge and tools to enable the primary care provider to understand the mechanism of anticoagulation and its reversal for oral vitamin K anticoagulants and the DOAC agents.

Case: An 82 year old male suffers a subdural hematoma after falling down a flight of concrete stairs. He is taking Warfarin. Past history remarkable for controlled HTN and diet-managed type 2 DM.

Outcome Objectives:

  • Characterize the mechanism of anticoagulation and its reversal for oral vitamin K anticoagulants and the DOAC agents

Funded through an educational grant from Portola Pharmaceuticals Inc.

Selection Required to View & Claim Credit

Anticoagulation Reversal: Case 4 - Stopping the Bleed - A 4 Step Approach
Presented by: Peter J. Kudenchuk, MD
Effective Date: August 15, 2017
Expiration Date: August 14, 2019
Credits: .5
Format: Webinar
Fee: Free
16887

This interactive case study discussion will provide the knowledge and tools to enable the primary care provider to understand the efficacy and limitations of current approaches to reversing anticoagulation in recipients of oral vitamin K antagonists and the mechanisms of the current reversal agents for DOACs and how they differ from approaches for reversal of vitamin K antagonists.

Case: A 59-year old male suffers a major GI bleed. He has been taking dabigatran for the past year for nonvalvular AF.

Outcome Objectives:

  • Describe the efficacy and limitations of current approaches to reversing anticoagulation in recipients of oral vitamin K antagonists
  • Characterize the mechanisms of the current reversal agents for DOACs and how they differ from approaches for reversal of vitamin K antagonists. 

Funded through an educational grant from Portola Pharmaceuticals Inc.

Selection Required to View & Claim Credit

Case Studies In Heart Failure
Presented by: Nicholas D. Wyatt, PharmD, Peter J. Kudenchuk, MD
Effective Date: February 01, 2017
Expiration Date: January 31, 2019
Credits: 2.5
Format: Webinar
Fee: $60.00
16747

Heart failure impacts the lives of thousands upon thousands of patients as well as their family members every year. The disease cost the healthcare system billions of dollars every year and is expected to continue to rise.

This course will give the participant the resources and tools necessary to become a heart failure expert. Our discussion will start with the epidemiology of heart failure. Then we will transition into discussing the stages of heart failure, specifically focusing on the four stages of heart failure and the evidence treatments of these four stages. Thanking you for joining me on your journey to becoming a heart failure expert. Let' get started.

Outcome Objectives
Upon completion of this CME/CE activity the healthcare provider will be able to:

  1. Describe the clinical epidemiology of heart failure and its impact on health care delivery and costs.
  2. List the modifiable risk factors of heart failure
  3. Identify the non-modifiable risk factors of heart failure
  4. Describe the population attribution risk of heart failure for modifiable and non-modifiable risk factors
  5. Define the four stages of the ACC/AHA heart failure staging model.
  6. Describe the four classification stages of the NYHA heart failure staging model.
  7. Describe the neurohormonal response in patients with and without heart failure.
  8. Identify key compensatory neurohormones in heart failure patients.
  9. Describe the renin-angiotension system response in patients with heart failure.
  10. List the compensatory responses that maintain circulation as a result of decreased cardiac output.
  11. Name two biomarkers used in the diagnosis and assessment heart failure.
  12. Discuss the four components of examining the heart failure patient.

To participate in this activity you must be Registered and Logged In to this website.

Selection Required to View & Claim Credit

Chronic Fatigue Syndrome and Hypothyroidism Are Linked To Low T3 Syndrome
Presented by: Neal Rouzier, MD
Effective Date: July 11, 2018
Expiration Date: July 11, 2020
Credits: 1.0
Format: Webinar
Fee: $30.00
17563

Dr. Rouzier, will be reviewing Chronic Fatigue Syndrome and how the signs and symptoms are similar, to hypothyroidism. How many times these conditions are misdiagnosed and how to interpret your patient's medical condition to improve clinical outcomes.

Outcome Objectives:
Upon completion of this CME/CE activity the healthcare provider will be able to:

  1. Review the work-up and diagnosis of Chronic Fatigue Syndrome.
  2. Recognize the many inflamed hormonal pathways in CFS.
  3. Discuss the pathophysiology involved in the development of CFS.
  4. Review thyroid lab tests as they pertain to CFS.
  5. Identify why it is called the hypometabolic syndrome.
  6. Review the studies that support normalizing TSH levels does NOT result in clinical euthyroidism.

To fully participate in this activity you must be Registered and Logged In to this website.

Selection Required to View & Claim Credit

HIV Update: Treatment as Prevention and Pre-exposure Prophylaxis
Presented by: Betsy Brown, MD, AAHIVS
Effective Date: March 05, 2016
Expiration Date: March 04, 2019
Credits: 1.0
Format: Webinar
Fee: $15.00
16134

This evidence-based course will provide you with the knowledge and tools to apply antiretrovirals in the prevention of transmission of HIV among at-risk individuals as well as in the treatment of HIV. It argues for treating STDs in the prevention of HIV and against the intermittent use of PrEP.

Outcome Objective
Upon completion of this CME activity the healthcare provider will be able to:

  1. Describe the viral transmission process in sexual transmission of HIV and the importance of treating STDs.
  2. Describe the action of Antiretroviral Therapy (ART).
  3. List and compare the components of pre-exposure and post-exposure prophylaxis, including obtaining an HIV baseline, and regular assessment of HIV status.
  4. Cite the reasons for advising against intermittent use of PrEP.
  5. Apply evidence-based protocols for the use of antiretrovirals for the prevention of transmission of HIV.
  6. Utilize the toolkits provided to insure that protocols are followed and to educate and counsel patients for better patient outcomes.

To participate in this activity you must be Registered and Logged In.

Funded through an educational grant from Gilead Sciences, Inc.

Selection Required to View & Claim Credit

Hypoglycemia: Decreasing the Rate of Hypoglycemia and Improving Patient Outcomes What the Primary Care Provider Needs to Know
Presented by: Lorena Alarcon-Casas Wright, MD
Effective Date: December 20, 2016
Expiration Date: December 19, 2018
Credits: 1.0
Format: Webinar
Fee: Free
16556

This one-hour internet course provides the knowledge and tools to enable the primary care provider and pharmacist to give evidence-based treatment and care to the patient experiencing hypoglycemia; to control and decrease hypoglycemic incidents and set as a major goal to improve the health status of diabetic patients at risk for hypoglycemia. A downloadable toolkit is also provided.

Outcome Objective
Upon completion of this CME/CE activity the healthcare provider will be able to:

  1. Define hyperglycemia, hypoglycemia, and severe hypoglycemia
  2. List inpatient glycemic targets in critical ill and non-critical ill patients
  3. Describe the treatment options available for achieving optimal glycemic targets in the critical ill and non-critical ill patients, utilizing a team-centric approach
  4. List causative factors of inpatient hypoglycemia and hyperglycemia
  5. Describe a multifaceted approach to reducing the occurrence of inpatient and outpatient hypoglycemia
  6. Design a treatment plan for a patient transitioning through the different phases of inpatient care and follow-up care
  7. Identify the cost effectiveness of inpatient hyperglycemic management

To participate in this activity you must be Registered and Logged In to this website.

ABIM MOC LogoSuccessful completion of this CME/CE activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Partially Funded through an educational grant from Novo Nordisk.

Selection Required to View & Claim Credit

Opioid Addiction: Challenging Cases in Diagnosis, Treatment, and Prevention
Presented by: Christine Mintz, MD
Effective Date: June 19, 2018
Expiration Date: June 19, 2020
Credits: 1.0
Format: Webinar
Fee: $30.00
17297

It is estimated that each day more than 1000 people are treated in emergency departments for not using prescription opioids as prescribed. Combine this with illicit drug use and the cost of treatment and productivity losses related to addiction and we have a current epidemic costing Americans over 500 billion dollars and rising.

This interactive course will give the participant the resources and tools necessary to identify, educate and treat opioid tolerant and opioid addicted patients in primary care. We will cover the pathophysiology of opioids and their receptors, then we will transition to discussing tolerance vs. withdrawal and addiction. We will also review overdose antagonist medications, medication assisted treatments as well as briefly discuss new treatments and research on the horizon.

Outcome Objectives:
Upon completion of this CME/CE activity the healthcare provider will be able to:

  1. Describe the pathophysiology of opioid receptors in the dopamine reward pathway and how different opioids and opioid antagonists interact and bind to these receptors.
  2. Describe the common clinical features of chronic opioid abuse and suspected opioid withdrawal including appropriate diagnostic work-up.
  3. Discuss the current best practice treatment options for suspected opioid overdose including routes of administration and formulations as well as medication assisted treatment options.
  4. Identify new or emerging areas of research and treatment options for opioid dependence including pharmacologic and psychosocial strategies.

To fully participate in this activity you must be Registered and Logged In to this website.

Selection Required to View & Claim Credit